High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. (Q42981955)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

M Biermer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

B Schlosser

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

B Fülöp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

F van Bömmel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

A Brodzinski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R Heyne

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

K Keller

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

C Sarrazin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

29 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

547-553

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

An updated systematic review with meta-analysis for the clinical evidence of silymarin

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Chemotherapy of Amanita phalloides poisoning with intravenous silibinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Multiple effects of silymarin on the hepatitis C virus lifecycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Performance of transient elastography for the staging of liver fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01572.X

10.1111/J.1365-2893.2011.01572.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762138%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference